Anish Patel Sells 716 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 716 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $30.00, for a total transaction of $21,480.00. Following the completion of the transaction, the chief operating officer now owns 343,311 shares in the company, valued at approximately $10,299,330. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Enliven Therapeutics Price Performance

ELVN traded up $0.08 during trading hours on Tuesday, hitting $28.95. 152,952 shares of the stock were exchanged, compared to its average volume of 260,665. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $30.03. The stock has a 50-day simple moving average of $24.23 and a 200-day simple moving average of $22.77. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -14.96 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. Sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ELVN. Janus Henderson Group PLC increased its holdings in Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Enliven Therapeutics by 49.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after acquiring an additional 37,632 shares during the last quarter. First Turn Management LLC bought a new stake in Enliven Therapeutics in the second quarter valued at approximately $9,657,000. American Century Companies Inc. boosted its position in Enliven Therapeutics by 44.7% during the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after acquiring an additional 8,540 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in Enliven Therapeutics in the second quarter worth about $322,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.